Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP ...

Experts say that improving heart and metabolic health may be key to helping people with severe mental illness live longer, ...

This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, ...

A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at ...

The GLP-1 moment signals how quickly a high-demand therapy can upend established care patterns—and how similar innovations may emerge in the years ahead.

Add Yahoo as a preferred source to see more of our stories on Google. GLP-1 agonists like Ozempic are primarily used to treat type 2 diabetes. Its popularity has even influenced wholesale retailer ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

Series D1 financing with participation from a syndicate of global healthcare-focused investors, including RTW Investments, SR One Capital ...

Young, affluent and health‑driven, GLP‑1 users are reshaping food retail with demand for protein‑rich, nutrient‑dense and convenient meals.

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p ...

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p 54% of participants on the 24 mg dose achieved resolution of obesity (BMI C ...

Glucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have gained popularity globally, not just for managing type 2 diabetes but also due to ...